
## CDK12-IN-6

Cat. No.:	HY-139329	F
CAS No.:	2651196-71-1	F⊸
Molecular Formula:	$C_{20}H_{21}F_2N_9$	н
Molecular Weight:	425.44	
Target:	CDK	
Pathway:	Cell Cycle/DNA Damage	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	a



ŇΗ

**Product** Data Sheet

BIOLOGICAL ACTIVITY					
Description	CDK12-IN-6, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC <sub>50</sub> of 1.19 μM at high ATP (2 mM). CDK12-IN-6 has no effect on CDK2/Cyclin E (IC <sub>50</sub> >20 μM) and CDK9/Cyclin T1 (IC <sub>50</sub> >20 μM) at high ATP (2 mM) (WO2021116178A1) <sup>[1]</sup> .				
$IC_{50}$ & Target	CDK12 1.19 μΜ (IC <sub>50</sub> )	CDK2/cyclinE >20 μM (IC <sub>50</sub> )	CDK9/cyclinT1 >20 μM (IC <sub>50</sub> )		
In Vitro	CDK12-IN-6 (Example 174) inhibits BRCA1 MRNA expression in MDA-MB-231 cells (IC <sub>50</sub> =0.872 nM) and has no effect on CAL- 120 cells <sup>[1]</sup> . CDK12-IN-6 has antproliferative activity in MDA-MB-231 cells (IC <sub>50</sub> =2.19 nM) and CAL-120 cells (IC <sub>50</sub> =1 nM) <sup>[1]</sup> . CDK12-IN-6 has a inhibition IC <sub>50</sub> CDK12 high ATP to Degradation DC <sub>50</sub> CDK12 ratio of 1851 <sup>[1]</sup> .				

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Kai Thede, et al. Pyrazolotriazines. WO2021116178A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA



E-mail: tech@MedChemExpress.com